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South Africa (SA) has the worst tuberculosis (TB) 
epidemic of any major country in the world, with 
>300  000 cases notified each year.[1] There are >6.1 
million people living with HIV (PLWH) in SA, 
and the country now has the largest antiretroviral 
treatment (ART) programme with >2 million people receiving 
combination therapy.[2] While there has been a marked recent decline 
in HIV-associated deaths,[2] >50% of TB cases still continue to be 
diagnosed in PWLH.[1] However, even HIV-uninfected individuals 
continue to develop active TB at rates as high as those recorded 
before the availability of chemotherapy.[3] The current TB control 
strategy based on passive case finding, chemotherapy of childhood 
TB contacts and directly observed therapy has clearly failed to control 
endemic TB in SA.[4] This critical situation has produced a body of 
policy makers who have proposed that TB control may be restored 
in part by expanding previously targeted preventive strategies to all 
PLWH,[1,5,6] or to whole communities.[7] Isoniazid (INH) prophylaxis of 
TB infection was first demonstrated in animal models in the 1950s,[8] 
studied in childhood contacts of TB cases in the 1960s[9] and became 
recommended for children <5 years of age with an adult household 
contact.[10] A combined analysis of randomised controlled trials 
(RCTs) of isoniazid preventive therapy (IPT) in (HIV-uninfected) 
adults performed between 1962 and 1994 demonstrated a reduction 
of active TB by 60% in a variety of recently TB-exposed or -infected 
populations.[11] A subsequent Cochrane meta-analysis of 12 RCTs 
of IPT in HIV-infected adults, largely without ART, showed a 62% 
reduction in TB, restricted to individuals with positive tuberculin 
skin tests (TSTs).[12] 
However, the World Health Organization (WHO) considered 
performing TSTs a stumbling block to the implementation of IPT 
and in 2011 revised the IPT guidelines, making a strong explicit 
recommendation that ‘TST was not a requirement for initiating 
IPT in PLWH’.[1] SA has implemented WHO policy and IPT is now 
recommended for all 6.1 million PLWH[2] for up to 36 months.[5,6] 
Originally, there was only one SA study included in the evidence 
base supporting this policy,[13] but subsequently four RCTs have 
been conducted in SA populations.[14-18] These, together with local 
observational studies, are the subject of this local data review. 
Mechanisms of IPT action
IPT is based on the widely accepted theory that primary infection 
with Mycobacterium tuberculosis is followed by a latent phase during 
which dormant tubercle bacilli may reactivate to cause TB disease. [19] 
INH sterilises these latent organisms. However, bacteriological 
latency may not correlate perfectly with clinical latency and a 
more dynamic balance between organism and host immunity may 
determine progression to active disease.[20] INH may act by altering 
this balance in favour of the host and against the organism. 
Tuberculin skin testing
The TST has remained the primary method for targeting IPT to 
those with known TB infection, but the TST is subject to both 
physiological and post-treatment reversions.[21] A positive TST in 
childhood generally reflects recent infection with a high risk of 
progression to active disease. In contrast, the majority of SA adults 
are latently infected and a positive TST reflects earlier TB infection, 
which is associated with a lowered risk of endogenous reactivation[22] 
and protection (79% confidence interval (CI) 70 - 86%) against 
TB re-infection progressing to active disease.[23] HIV-infection 
increases TB incidence,[24] but TST-positivity decreases as CD4+ cell 
counts decline.[25] While ART improves CD4+ cell counts[26] and TB 
immunity,[27] the changes in the TST during ART have not been well 
characterised.
Challenges for IPT implementation
In contrast to the implementation of the ART programme, non-
targeted IPT implementation has been very poor.[28] Rationale for the 
reticence to implement IPT include: that short-term trial efficacy 
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data preceded widespread introduction of ART and may lack current 
relevance; TST-positive ART-naive individuals who were the subgroup 
with demonstrable benefit, constitute only a minority of PLWH;[25] the 
TST-negative majority of PLWH may be subjected to therapy without 
personal benefit; any sustained benefit is considerably reduced in SA where 
the ongoing risk of TB re-infection is high; lack of long-term effectiveness 
limits potential epidemiological impact; where service delivery falls short 
of desired levels, the implementation of IPT may overburden the healthcare 
system and divert attention from more effective treatment priorities; INH 
is an important component of standard TB treatment, resistance is already 
high and clinical experience has shown that widespread use of antibiotics is 
inevitably followed by increasing drug resistance, a concern reinforced by a 
recent modelling study of the long-term impact of community-wide IPT.[29]
RCTs in SA
SA clinical scientists have performed several large and well-conducted RCTs 
of IPT, which have contributed significantly to the existing body of scientific 
evidence and are summarised in Table 1.
Two RCTs have been performed in SA paediatric populations. The first; 
randomised 263 HIV-positive children, recruited in two Cape Town teaching 
hospitals, to daily or thrice-weekly IPT or placebo.[14] The children had 
advanced symptomatic HIV manifested by low weight-for-age and height. 
The study was discontinued because of an early survival benefit largely in the 
first 6 months in the IPT arm compared with the control arm. TB incidence 
was also reduced in the intervention arm by 72%. Few of the children were 
receiving ART at baseline because the study was conducted prior to wide 
access to ART. Diagnosis of TB in sick HIV-infected infants is difficult and 
the early mortality benefit observed in this study may have resulted from 
INH treatment of unrecognised primary TB.[30]
A second paediatric RCT, a primary prevention with 96 weeks IPT v. 
placebo, was conducted in 548 HIV-infected and 804 HIV-exposed children 
<4 months of age, recruited from hospital clinics in Johannesburg, Cape 
Town and Durban.[15] The HIV-infected children in this study were less sick 
than in the prior study and ART use was higher, with 99% commencing 
ART during the study. There was no difference in TB infection, TB disease 
or death between the INH and control arms in either HIV-infected or HIV-
exposed children. INH resistance was noted in 28% of TB cases. 
The very different outcomes in these two paediatric studies underscore 
the importance of exercising great care when generalising beyond the 
population under study.[29] The study populations differed by age, severity of 
HIV disease, nutritional status and ART use, as illustrated by very different 
TB and mortality rates in the control arms of each study. 
The single SA study included in the Cochrane review[12] was an RCT of 
IPT given twice weekly to TST-negative, HIV-infected adults, all of whom 
were anergic.[13] The study, which was conducted before ART availability in 
a population with advanced HIV disease, showed no effect on mortality or 
TB incidence.[13] The majority of screened subjects were TST-negative and 
the 17% of subjects with a positive TST who qualified for IPT under existing 
guidelines had much higher CD4+ cell counts than those in the randomised 
study population. The statistical power of the study was reduced, as TB 
incidence rate in the study was considerably lower than reported previously, 
probably due to exclusion of TB cases treated within the previous 5 years and 
baseline TB screening including sputum culture.
Over 2 000 patients attending an ART clinic in Cape Town were assessed 
for entry into an RCT with 12 months IPT.[16] Of the 1  536 otherwise 
consenting and eligible patients, 250 were diagnosed with prevalent active 
TB disease by screening, including sputum culture, at baseline. Of the 
finally enrolled population, 43% reported a history of prior TB, only 30% 
were TST-positive and the majority was already established receiving ART 
before initiating IPT. During a follow-up of mean 2.4 years, 37 and 58 
incident cases were identified in the IPT and control arms, respectively; 
(hazard ratio (HR) 0.62; 95% CI 0.41 - 0.94). Drug-resistance testing 
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identified INH resistance in 6/25 (24%) cases tested. All-cause 
mortality did not differ between intervention and control arms. In 
secondary analysis there was no evidence that the effect of IPT was 
restricted to those who were TST-positive. The authors concluded 
that the ‘  … modest effects described and the high rate of TB in 
the IPT arm, suggest ART plus IPT alone may not be adequate to 
control TB at the population level’.
These two studies again underscore the hazard of generalising 
beyond any study population, as it appears that the predictive 
value of TST testing for IPT may be more important before ART 
when immunity is deteriorating than after ART when immunity is 
improving. TB screening in both studies had a very high yield of TB 
cases. 
A very large community-wide RCT in SA miners randomised 
the workforce of eight mineshafts to receive 9 months of IPT and 
of seven mineshafts to receive placebo. The primary endpoint was 
TB incidence during the following year and secondary endpoint TB 
prevalence at the study end.[7] The placebo clusters were screened 
within the normal mining healthcare service but those in the IPT arm 
underwent more intensive TB screening.[31] There were no differences 
in either primary or secondary endpoints between treatment and 
control arms.[17,18] A post hoc analysis of participants commencing IPT 
in the intervention cohort had a temporary non-sustained decrease 
in TB incidence compared with controls.[17,18] The positive results of 
the post hoc analysis were attributed to a temporary benefit of IPT. 
However, the differential screening procedures between the two 
study arms did not allow for attribution of benefit to either IPT or to 
intensified TB screening. A laboratory sub-study of INH resistance 
reported 12% resistance in first TB cases but no significant increase 
in the IPT arm compared with the control group.[32]
Observational studies in SA 
A large observational study (N=2 778) in urban and rural SA compared 
TB-free survival during a mean of 1.5 years, split into time accrued 
receiving IPT, ART, and IPT with ART, and reported a significantly high 
effectiveness of IPT in combination with ART.[33] Exceptionally wide 
confidence limits and selection bias did not support the conclusion of 
significant IPT benefit.[34] A second large observational study of 3 270 
workers in an occupational health setting reported a 49% reduction 
in mortality associated with receipt of IPT prior to or during ART.[35] 
The HR remained significant after adjustment for clinical parameters, 
CD4+ cell count, calendar year and employing company. Although the 
authors’ reporting of a halving of mortality by IPT was plausible among 
individuals initiating ART in a setting of high TB incidence,[35] no 
similar mortality benefit of additional IPT with ART has been reported 
in any randomised adult study.
Implications of local studies
Variable study results can provoke one of two scientific responses: to 
look harder within our existing theory with even larger and longer 
studies with more meta-analyses; or alternatively, to question our 
basic biological and epidemiological assumptions. Much of the inter-
study variability in IPT efficacy can be explained by differential 
baseline screening procedures, differential use of ART and different 
TB exposures. The two studies, which screened all participants with 
TB culture, reported much lower TB rates in the control arms than 
predicted.[13,16] The control arm of the mining study with no additional 
TB screening at baseline was followed by TB incidence similar to 
historic levels.[17] Intensified baseline TB screening in the IPT arm that 
identified and excluded an additional 1 705 (6.9%) prevalent TB cases 
was followed by a transient lowered TB incidence. [17] Additionally, the 
magnitude of the prevalent TB cases identified by intensified screening 
was two-fold higher than all the cases identified during each of these 
studies and far exceeded the numbers of cases prevented by IPT. 
Studies with ART had much lower clinical event frequencies 
in both paediatric and adult studies than those without ART. 
Furthermore, INH performed different biological roles, each 
with differential efficacy, in the different populations including: 
prophylaxis both before and after a known TB exposure; treatment 
of childhood primary TB; sterilisation of recent or distantly acquired 
‘latent’ infection; and treatment of either pauci- or multibacillary 
adult disease. Table 2 outlines a conceptual framework of the different 
population groups in each of the studies. While in the TB-susceptible 
paediatric populations, stratification can be by known TB exposure 
(household contact) and primary disease (symptomatic), adult 
studies are stratified by TST status which, in an already infected 
population, reflects distantly acquired primary infection, but also TB 
re-infection and in PLWH, immune decline and recovery before and 
after ART, respectively. 
Treatment of active TB disease with INH monotherapy will occur 
more frequently in situations where TB diagnosis is difficult or when 
screening procedures are less stringent. Paediatric TB diagnosis is 
difficult; therefore undiagnosed primary TB would be highest in 
symptomatic HIV disease, lower in asymptomatic HIV disease and 
lowest in the asymptomatic HIV-uninfected children. 
All TST-negative adult subjects prior to ART were anergic, a 
reflection of poor immunity rather than identification of a group 
without prior TB infection. It is unclear how TST-positivity after 
Table 2. Study populations by HIV, TST and probable TB exposure
Paediatric subjects HIV status Pre-primary exposure* Known primary exposure Primary disease*
Zar et al.[14] Positive ++ Excluded ++
Madhi et al.[15] Positive +++ Excluded +
Negative +++ Excluded +
Adult subjects HIV status TST-negative* TST-positive: Recent* TST-positive: Distant*
Mohammed et al.[13] Positive +++
Positive +++
Rangaka et al.[16] Positive ++ +/- ++
Churchyard et al.[17] Positive ++ +/- ++
Negative ++ +/- +++
TST = tuberculin skin test; TB = tuberculosis; ARI = annual risk of TB infection.
*Estimated frequencies: +/- determined by the ARI; + determined by ARI and rate of progression of primary infection to active TB; ++: 10 - 50%;  +++: >50%.
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initiating ART reflects immune recovery or new TB exposures. 
However, TSTs appeared to identify groups with different responses 
to IPT pre and post ART. Extrapolation of results from the pre-ART 
era may now lack relevance in an era of greater access to ART. 
The observation that INH resistance was not increased in well-
conducted IPT studies in which screening procedures ensured 
unrecognised active TB was minimal;[31] is not necessarily reassuring 
for future scenarios where IPT is given to 6.1 million PLWH without 
similar screening procedures.[5,6] 
Conclusions
The total lack of IPT efficacy in the community-wide study, and 
only modest benefits in the ART clinic population, indicate that 
hopes that IPT would positively impact the TB epidemic in SA are 
optimistic. Intensified TB screening at study entry identified a large 
number of previously unrecognised TB cases, was associated with 
a decrease in subsequent TB incidence and identified many more 
cases than occurred during the course of the studies. Of concern, the 
prevalence of INH resistance was high in all those studies where it 
was measured. Therefore expansion of IPT to all PLWH in SA must 
be associated with efficient TB screening and monitoring of INH 
resistance. Importantly, implementation of this modestly beneficial 
intervention should not divert us from the priority to increase 
access to ART urgently and reduce the treatment gap. TB control 
will require a new focus on reducing ongoing transmission, which 
results in the majority of our population becoming TB infected before 
adulthood.[36] 
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